[1] |
Bolognia JL, Schaffer JV, Cerroni L. Dermatology [M]. 4th ed. New York: Elsevier, 2018:208⁃227.
|
[2] |
Katoh N, Ohya Y, Ikeda M, et al. Clinical practice guidelines for the management of atopic dermatitis 2018[J]. J Dermatol, 2019,46(12):1053⁃1101. doi: 10.1111/1346⁃8138.15090.
|
[3] |
Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis[J]. Nat Rev Dis Primers, 2018,4(1):1. doi: 10.1038/s41572⁃018⁃0001⁃z.
|
[4] |
陈东宇, 杨晓雨, 王红心, 等. 中国居民1990⁃2019年皮肤及皮下疾病疾病负担变化趋势[J]. 中国公共卫生, 2022,38(5):529⁃533. doi: 10.11847/zgggws1137391.
|
[5] |
Dong WL, An J, Yu M, et al. The prevalence and year lived with disability of atopic dermatitis in China: findings from the global burden of disease study 2019[J]. World Allergy Organ J, 2021,14(11):100604. doi: 10.1016/j.waojou.2021.100604.
|
[6] |
Moon R, Kragh N, Troensegaard⁃Petersen N, et al. Flaring among atopic dermatitis patients ⁃ the perception of flaring burden between physicians and patients[J]. Value in health, 2017,20(9): A547.
|
[7] |
Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis[J]. J Allergy Clin Immunol, 2006,118(1):226⁃232. doi: 10.1016/j.jaci.2006.02.031.
|
[8] |
Gorritz M, Boytsov NN, Goldblum OM, et al. Inadequate response and treatment patterns in adults diagnosed with atopic dermatitis and treated with topical therapy[J]. J Dermatolog Treat, 2022,33(5):2510⁃2517. doi: 10.1080/09546634.2021.19 81813.
|
[9] |
Bruin⁃Weller M, Pink AE, Patrizi A, et al. Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study[J]. J Dermatolog Treat, 2021,32(2):164⁃173. doi: 10.1080/09546634.2020.186 6741.
|
[10] |
Wei W, Anderson P, Gadkari A, et al. Extent and consequences of inadequate disease control among adults with a history of moderate to severe atopic dermatitis[J]. J Dermatol, 2018,45(2):150⁃157. doi: 10.1111/1346⁃8138.14116.
|
[11] |
Armstrong AW, Huang A, Wang L, et al. Real⁃world utilization patterns of systemic immunosuppressants among US adult patients with atopic dermatitis[J/OL]. PLoS One, 2019,14(1):e0210517. doi: 10.1371/journal.pone.0210517.
|
[12] |
Wei W, Ghorayeb E, Andria M, et al. A real⁃world study evaluating adeQUacy of Existing Systemic Treatments for patients with moderate⁃to⁃severe Atopic Dermatitis (QUEST⁃AD): baseline treatment patterns and unmet needs assessment[J]. Ann Allergy Asthma Immunol, 2019,123(4):381⁃388. doi: 10.1016/j.anai.2019.07.008.
|
[13] |
Puar N, Chovatiya R, Paller AS. New treatments in atopic dermatitis[J]. Ann Allergy Asthma Immunol, 2021,126(1):21⁃31. doi: 10.1016/j.anai.2020.08.016.
|
[14] |
Renert⁃Yuval Y, Guttman⁃Yassky E. New treatments for atopic dermatitis targeting beyond IL⁃4/IL⁃13 cytokines[J]. Ann Allergy Asthma Immunol, 2020,124(1):28⁃35. doi: 10.1016/j.anai.2019.10.005.
|
[15] |
Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease[J]. Nat Rev Drug Discov, 2022,21(1):21⁃40. doi: 10.1038/s41573⁃021⁃00266⁃6.
|
[16] |
De Bruin⁃Weller M, Biedermann T, Bissonnette R, et al. Treat⁃to⁃target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies[J]. Acta Derm Venereol, 2021,101(2):adv00402. doi: 10.2340/00015555⁃3751.
|
[17] |
赵作涛, 高兴华. 中重度特应性皮炎系统药物达标治疗专家指导建议[J]. 中国皮肤性病学杂志, 2022,36(8):855⁃864. doi: 10.13735/j.cjdv.1001⁃7089.202205115.
|
[18] |
Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis[J].Acta Dermatovener(Stockholm), 1980,92(suppl):44⁃47. doi:10.2340/00015555924447.
|
[19] |
Williams HC, Burney PG, Hay RJ, et al. The U.K. Working Party′s Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis[J]. Br J Dermatol, 1994,131(3):383⁃396. doi: 10.1111/j.1365⁃2133.1994.tb08530.x.
|
[20] |
Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis[J]. J Am Acad Dermatol, 2014,70(2):338⁃351. doi: 10.1016/j.jaad.2013.10.010.
|
[21] |
Liu P, Zhao Y, Mu ZL, et al. Clinical features of adult/adolescent atopic dermatitis and Chinese criteria for atopic dermatitis[J]. Chin Med J (Engl), 2016,129(7):757⁃762. doi: 10.4103/0366⁃6999.178960.
|
[22] |
Cheng R, Zhang H, Zong W, et al. Development and validation of new diagnostic criteria for atopic dermatitis in children of China[J]. J Eur Acad Dermatol Venereol, 2020,34(3):542⁃548. doi: 10.1111/jdv.15979.
|
[23] |
Schmitt J, Spuls P, Boers M, et al. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting[J]. Allergy, 2012,67(9):1111⁃1117. doi: 10.1111/j.1398⁃9995.2012.02874.x.
|
[24] |
Leshem YA, Chalmers JR, Apfelbacher C, et al. Measuring atopic eczema symptoms in clinical practice: the first consensus statement from the harmonising outcome measures for eczema in clinical practice initiative[J]. J Am Acad Dermatol, 2020,82(5):1181⁃1186. doi: 10.1016/j.jaad.2019.12.055.
|
[25] |
Werfel T, Heratizadeh A, Aberer W, et al. Update "Systemic treatment of atopic dermatitis" of the S2k⁃guideline on atopic dermatitis[J]. J Dtsch Dermatol Ges, 2021,19(1):151⁃168. doi: 10.1111/ddg.14371.
|
[26] |
Boguniewicz M, Alexis AF, Beck LA, et al. Expert perspectives on management of moderate⁃to⁃severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies[J]. J Allergy Clin Immunol Pract, 2017,5(6):1519⁃1531. doi: 10.1016/j.jaip.2017.08.005.
|
[27] |
Yosipovitch G, Reaney M, Mastey V, et al. Peak pruritus numerical rating scale: psychometric validation and responder definition for assessing itch in moderate⁃to⁃severe atopic dermatitis[J]. Br J Dermatol, 2019,181(4):761⁃769. doi: 10.1111/bjd.17744.
|
[28] |
Silverberg JI, Lei D, Yousaf M, et al. What are the best endpoints for eczema area and severity index and scoring atopic dermatitis in clinical practice? A prospective observational study[J]. Br J Dermatol, 2021,184(5):888⁃895. doi: 10.1111/bjd. 19457.
|
[29] |
Silverberg JI, Lei D, Yousaf M, et al. Measurement properties of the product of investigator′s global assessment and body surface area in children and adults with atopic dermatitis[J]. J Eur Acad Dermatol Venereol, 2021,35(1):180⁃187. doi: 10.1111/jdv.16846.
|
[30] |
Suh TP, Ramachandran D, Patel V, et al. Product of Investigator Global Assessment and Body Surface Area (IGAxBSA): a practice⁃friendly alternative to the Eczema Area and Severity Index to assess atopic dermatitis severity in children[J]. J Am Acad Dermatol, 2020,82(5):1187⁃1194. doi: 10.1016/j.jaad.2020.01.023.
|
[31] |
Schram ME, Spuls PI, Leeflang MM, et al. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference[J]. Allergy, 2012,67(1):99⁃106. doi: 10.1111/j.1398⁃9995.2011.02719.x.
|
[32] |
Basra MK, Salek MS, Camilleri L, et al. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data[J]. Dermatology, 2015,230(1):27⁃33. doi: 10.1159/000365390.
|
[33] |
中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南(2020版)[J]. 中华皮肤科杂志, 2020,53(2):81⁃88. doi: 10.35541/cjd.20191000.
|
[34] |
Torres T, Gonçalo M, Paiva Lopes MJ, et al. Portuguese recommendations for the treatment of atopic dermatitis with biologic therapy and JAK inhibitors in adult patients[J]. Drugs Context, 2021,10:2021⁃2029⁃5. doi: 10.7573/dic.2021⁃9⁃5.
|
[35] |
EuroGuiDerm Centre for Guideline Development. EuroGuiDerm Guideline on atopic eczema. Version 2.0[EB/OL].[2023⁃04⁃28]. https://guidelines.edf.one//guidelines/living⁃euroguiderm⁃guideline⁃for⁃the⁃systemic⁃treatment⁃of⁃atopic⁃eczema⁃2.
|
[36] |
Wollenberg A, Christen⁃Zäch S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children[J]. J Eur Acad Dermatol Venereol, 2020,34(12):2717⁃2744. doi: 10.1111/jdv.16892.
|
[37] |
中国医师协会皮肤科医师分会自身免疫病专业委员会. 环孢素治疗免疫相关性皮肤病专家建议[J]. 中华皮肤科杂志, 2022,55(6):471⁃479. doi: 10.35541/cjd.20210434.
|
[38] |
颜克香. 甲氨蝶呤在皮肤科的临床应用及注意事项[J]. 皮肤科学通报, 2021,38(4):320⁃326.
|
[39] |
中国医师协会皮肤科医师分会自身免疫病专业委员会. 甲氨蝶呤治疗免疫相关性皮肤病专家共识[J]. 中华皮肤科杂志, 2021,54(5):382⁃390. doi: 10.35541/cjd.20200796.
|
[40] |
张佩莲,叶建州.度普利尤单抗治疗特应性皮炎的不良反应与防治对策[J/OL].中国皮肤性病学杂志, 2022. (2022⁃10⁃19)[2023⁃04⁃28]. https://doi.org/10.13735/j.cjdv.1001⁃7089. 202207104.
|
[41] |
Marcant P, Balayé P, Merhi R, et al. Dupilumab⁃associated hypereosinophilia in patients treated for moderate⁃to⁃severe atopic dermatitis[J]. J Eur Acad Dermatol Venereol, 2021,35(6):e394⁃e396. doi: 10.1111/jdv.17177.
|
[42] |
Inokuchi⁃Sakata S, Ishiuji Y, Katsuta M, et al. Role of eosinophil relative count and neutrophil⁃to⁃lymphocyte ratio in the assessment of severity of atopic dermatitis[J]. Acta Derm Venereol, 2021,101(7):adv00491. doi: 10.2340/00015555⁃3838.
|
[43] |
中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组, 中国老年保健医学研究会皮肤科分会. 系统Janus激酶抑制剂治疗特应性皮炎专家共识[J]. 实用皮肤病学杂志, 2022,15(3):129⁃135. doi: 10.11786/sypfbxzz.1674⁃1293.202 20301.
|